Mirae Asset Global Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.5M | Buy |
61,531
+5,140
| +9% | +$1.55M | 0.03% | 320 |
|
|
2026
Q1 | $18.7M | Buy |
56,391
+6,929
| +14% | +$2.36M | 0.01% | 279 |
|
|
2025
Q4 | $19.7M | Buy |
49,462
+43,302
| +703% | +$19.2M | 0.05% | 280 |
|
|
2025
Q3 | $2.81M | Buy |
6,160
+1,385
| +29% | +$564K | 0.01% | 654 |
|
|
2025
Q2 | $1.56M | Sell |
4,775
-1,759
| -27% | -$487K | 0.01% | 754 |
|
|
2025
Q1 | $1.76M | Sell |
6,534
-2,596
| -28% | -$667K | 0.01% | 711 |
|
|
2024
Q4 | $2.16M | Sell |
9,130
-1,298
| -12% | -$341K | 0.01% | 639 |
|
|
2024
Q3 | $2.87M | Sell |
10,428
-2,764
| -21% | -$720K | 0.01% | 525 |
|
|
2024
Q2 | $3.26M | Sell |
13,192
-49,223
| -79% | -$7.77M | 0.02% | 464 |
|
|
2024
Q1 | $11.2M | Buy |
62,415
+24,228
| +63% | +$4.04M | 0.02% | 594 |
|
|
2023
Q4 | $7.34M | Sell |
38,187
-22,532
| -37% | -$3.84M | 0.01% | 764 |
|
|
2023
Q3 | $10.7M | Buy |
60,719
+2,268
| +4% | +$433K | 0.02% | 583 |
|
|
2023
Q2 | $11.1M | Sell |
58,451
-7,483
| -11% | -$1.48M | 0.02% | 605 |
|
|
2023
Q1 | $13.2M | Buy |
65,934
+7,604
| +13% | +$1.6M | 0.03% | 526 |
|
|
2022
Q4 | $13.9M | Sell |
58,330
-14,361
| -20% | -$3.06M | 0.04% | 488 |
|
|
2022
Q3 | $14.6M | Buy |
72,691
+4,920
| +7% | +$938K | 0.04% | 437 |
|
|
2022
Q2 | $9.88M | Buy |
67,771
+2,199
| +3% | +$312K | 0.03% | 607 |
|
|
2022
Q1 | $10.7M | Sell |
65,572
-9,597
| -13% | -$1.46M | 0.02% | 651 |
|
|
2021
Q4 | $12.8M | Sell |
75,169
-9,294
| -11% | -$1.73M | 0.03% | 604 |
|
|
2021
Q3 | $15.9M | Buy |
84,463
+16,867
| +25% | +$3.16M | 0.04% | 468 |
|
|
2021
Q2 | $11.5M | Buy |
67,596
+11,732
| +21% | +$1.72M | 0.03% | 580 |
|
|
2021
Q1 | $7.89M | Buy |
55,864
+24,215
| +77% | +$3.64M | 0.03% | 612 |
|
|
2020
Q4 | $4.11M | Buy |
31,649
+15,194
| +92% | +$2.03M | 0.02% | 703 |
|
|
2020
Q3 | $2.4M | Buy |
16,455
+3,063
| +23% | +$435K | 0.01% | 743 |
|
|
2020
Q2 | $1.98M | Buy |
13,392
+3,253
| +32% | +$439K | 0.01% | 702 |
|
|
2020
Q1 | $1.1M | Buy |
10,139
+1,085
| +12% | +$125K | 0.01% | 801 |
|
|
2019
Q4 | $1.04M | Buy |
9,054
+408
| +5% | +$40.7K | 0.01% | 949 |
|
|
2019
Q3 | $695K | Buy |
8,646
+5,452
| +171% | +$431K | ﹤0.01% | 1053 |
|
|
2019
Q2 | $231K | Buy |
+3,194
| New | +$245K | ﹤0.01% | 1339 |
|
|
2016
Q4 | – | Sell |
-8,194
| Closed | -$556K | – | 506 |
|
|
2016
Q3 | $556K | Sell |
8,194
-2,880
| -26% | -$203K | 0.01% | 423 |
|
|
2016
Q2 | $615K | Sell |
11,074
-2,247
| -17% | -$142K | 0.02% | 374 |
|
|
2016
Q1 | $836K | Buy |
13,321
+10,348
| +348% | +$688K | 0.02% | 349 |
|
|
2015
Q4 | $280K | Buy |
+2,973
| New | +$276K | 0.01% | 400 |
|
|
2015
Q3 | – | Sell |
-2,149
| Closed | -$258K | – | 438 |
|
|
2015
Q2 | $258K | Buy |
2,149
+145
| +7% | +$17.3K | 0.01% | 423 |
|
|
2015
Q1 | $209K | Buy |
+2,004
| New | +$203K | 0.01% | 450 |
|
Other funds holding ALNY
CAM
Mirae Asset Global Investments's ALNY Position: Q2 2026 in Review
Mirae Asset Global Investments increased its Alnylam Pharmaceuticals (ALNY) stake by 9.1% in Q2 2026, buying an estimated $1.55M and bringing the position to 61,531 shares worth $18.5M. The position accounts for 0.03% of the portfolio, ranked #320.
Mirae Asset Global Investments first reported a position in ALNY in Q1 2015 and has held it in 35 quarters since. The position peaked at $19.7M in Q4 2025. 365 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Mirae Asset Global Investments held 61,531 shares of Alnylam Pharmaceuticals worth $18.5M as of Q2 2026.
- Mirae Asset Global Investments bought 5,140 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.55M.
- Alnylam Pharmaceuticals made up 0.03% of Mirae Asset Global Investments's portfolio in Q2 2026, its #320 holding.
- Mirae Asset Global Investments first reported a position in Alnylam Pharmaceuticals in Q1 2015 and has held it in 35 quarters since.
- Mirae Asset Global Investments's Alnylam Pharmaceuticals position peaked at $19.7M in Q4 2025.
- 365 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.